NEW YORK, Aug. 14 - Testing for disease susceptibility will account for one-third of the total genomic-diagnostic revenues this year, according to a report released today.
The report, by health-care research firm Decision Resources, shows that revenues from sales of assays for disease-susceptibility testing, prognostics, and monitoring are projected to reach $115 million in 2002 from an estimated $71 million collected last year. If fulfilled, this forecast means that these applications will account for about 90 percent of the total genomic-diagnostics market.
Companies that currently occupy the genomics-diagnostics space include Affymetrix, Cepheid, DNA Sciences, Myriad Genetics, Nanogen, and Third Wave Technologies.
Still, "there aren't many [of these] products on the market right now," Karen O'Connor, an analyst with Decision Resources, told GenomeWeb. "These estimates have ... been based on products that have not come out to market yet."